CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

Prior treatment

• Long-term use of methotrexate, corticosteroids, anti-Tumor Necrosis Factor cyclosporine, tacrolimus

Other illness

• Positive HIV serology
• Patients with detectable hepatitis C viral load
• History of autoimmune hepatitis type 1 or 2, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, genetic haemochromatosis homozygous, alpha1 anti-trypsin deficiency
• History of solid organ transplantation or bone marrow transplantation
• Cancerous disease in the process of being treated, except for skin cancer (excluding melanoma)

Other

• Presence of Hbs antigen
• Patients under legal protection or unable to express their consent,
• Pregnant or breastfeeding women

• Criteria common to all patients:
  • Affiliation to French social security.
  • Male or female ≥ 18 years of age
  • Patients able to receive and understand information about the research and to give written informed consent duly signed by the patient and the investigator (at the latest on the day of inclusion and before any examination necessary for the research).
• Patients in the NAFLD group with HCC:
  • Alcohol consumption ≤ 30 g pure alcohol/d (or 210 g pure alcohol/week) for men and ≤ 20 g pure alcohol/d (140 g pure alcohol/week) for women.
  • Decision, less than 3 months old, of liver biopsy of the suspected HCC nodule and non-tumour liver tissue performed as a clinical routine.
  • No systemic treatment for HCC within 6 months prior to inclusion.
• Patients in the NAFLD group without HCC:
  • Alcohol consumption ≤ 30 g pure alcohol/d (or 210 g pure alcohol/week) for men and ≤ 20 g pure alcohol/d (140 g pure alcohol/week) for women.
  • Decision of less than 3 months of a liver biopsy performed as a clinical routine. Biopsy will be motivated by liver function disturbance(s) and/or ultrasound steatosis given the lack of validated non-invasive tests or the lack of accuracy (grey areas) of available non-invasive tests for the diagnosis of necro-inflammation and/or fibrosis in some of these patients.
• Patients in the alcohol-related liver disease group with HCC:
  • Alcohol consumption \> 30 g pure alcohol/d (or 210 g pure alcohol/week) for men and \> 20 g pure alcohol/d (140 g pure alcohol/week) or binge drinking
  • Decision within 3 months of liver biopsy of suspected HCC nodule and non-tumour liver tissue performed as part of clinical routine
  • No systemic treatment for HCC within 6 months prior to inclusion.
• Patients in the alcohol-related liver disease group without HCC:
  • Alcohol consumption \> 30 g pure alcohol/d (or 210 g pure alcohol/week) for men and \> 20 g pure alcohol/d (140 g pure alcohol/week) or binge drinking
  • Decision of less than 3 months for a liver biopsy to be performed as a clinical routine. Biopsy will be motivated by liver balance disturbance(s) and/or ultrasound steatosis given the lack of validated non-invasive tests or the lack of accuracy (grey areas) of available non-invasive tests for the diagnosis of necro-inflammation and/or fibrosis in some of these patients.